
Release date: 2025-12-31 15:42:42 Article From: Lucius Laos Recommended: 174
Ivosidenib is indicated only for patients with acute myeloid leukemia (AML), cholangiocarcinoma, or myelodysplastic syndromes (MDS) whose tumors harbor an isocitrate dehydrogenase-1 (IDH1) mutation. Your doctor will perform testing to confirm the presence of this mutation.
Your doctor must schedule regular follow-up visits to ensure the medication is working effectively. Blood and urine tests may be required to monitor for potential adverse reactions.
Taking this medication may increase your risk of developing a condition called differentiation syndrome, which can be life-threatening. This typically occurs within 1 day to 3 months after starting treatment. Contact your doctor immediately if you experience any of the following symptoms: fever, cough, difficulty breathing, swelling in your arms or legs, swelling around your neck, groin, or armpits, rapid weight gain, or bone pain.
This drug may also cause a serious reaction known as tumor lysis syndrome (TLS). Seek immediate medical attention if you notice changes in the amount or frequency of urination, rapid weight gain, muscle or joint pain, swelling in your feet or lower legs, or unusual fatigue or weakness.
1. Your condition will be closely monitored throughout your treatment with this drug.
2. You may feel unwell during treatment. This is not uncommon, as chemotherapy medications affect not only cancer cells but also healthy cells. Report any side effects to your healthcare team. Unless instructed otherwise by your medical team, continue taking the full prescribed course even if you feel unwell.
3. You may need periodic blood tests during treatment.
4. Inform your healthcare team if you are pregnant or could become pregnant. Taking this medication during pregnancy may cause severe birth defects. Use effective contraception during treatment. Your healthcare team can help you choose an appropriate method of birth control.
5. Do not breastfeed during treatment and for at least 1 month after your last dose.
6. This medication may cause infertility. If you have concerns about your fertility, discuss them with your healthcare team.
Keep the medication out of reach of children and pets.
Store it at room temperature between 20°C and 25°C (68°F to 77°F) in a dry place. Keep the container tightly closed. Do not discard the desiccant packet inside the bottle—it helps keep the medication dry. Dispose of any unused medication after the expiration date.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: